Aligos Therapeutics Inc (NAS:ALGS)
$ 0.5998 0.0198 (3.41%) Market Cap: 46.85 Mil Enterprise Value: -56.95 Mil PE Ratio: 0 PB Ratio: 0.79 GF Score: 51/100

Aligos Therapeutics Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript

Feb 15, 2023 / 08:00PM GMT
Release Date Price: $1.62 (-0.61%)
Roanna Ruiz
SVB Securities - Analyst

Great. Welcome back everyone to our next session. I'm Roanna Ruiz, senior biotech analyst here at SVB Securities. And it's my pleasure to introduce the Chairman and CEO of Aligos Therapeutics, Lawrence Blatt. So thanks for joining us. And I will pass it to Lawrence to kick off a presentation on the company.

Lawrence Blatt
Aligos Therapeutics, Inc. - Chairman & CEO

Thank you, and I want to thank you and the Silicon Valley Bank team for inviting us to this presentation.

So we will be making forward-looking statements today about our portfolio. The Aligos' portfolio consists of several products in early clinical development. Our lead asset in NASH is ALG-009, and this was a in-house discovered purpose-built beta thyroid agonist. We began working on this program about five years ago. And we're just completing our Phase 1 studies and moving into Phase 2 studies.

And I think as most of the audience knows, there's been a recent development for beta thyroid agonism and that is the lead compound for Madrigal

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot